Does the media favor SRPT or PRTA?

In the previous week, Sarepta Therapeutics had 9 more articles in the media than Prothena. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Sarepta Therapeutics' score of 1.00 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, PRTA or ZYME?

Zymeworks has higher revenue and earnings than Prothena. Zymeworks is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 50.46 -$244.09M -$0.84 N/A Zymeworks $105.96M 18.93 -$81.13M -$2.02 N/A

Is PRTA or ZYME more profitable?

Prothena has a net margin of -80.68% compared to Zymeworks' net margin of -405.31%. Prothena's return on equity of -16.45% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Zymeworks -405.31% -72.30% -37.18%

Does the media favor PRTA or ZYME?

In the previous week, Zymeworks had 32 more articles in the media than Prothena. MarketBeat recorded 35 mentions for Zymeworks and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Zymeworks' score of 0.91 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zymeworks 12 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PRTA or KARD?

Kardigan has lower revenue, but higher earnings than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 50.46 -$244.09M -$0.84 N/A Kardigan N/A N/A N/A N/A N/A

Is PRTA or KARD more profitable?

Kardigan has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Kardigan's return on equity of 0.00% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Kardigan N/A N/A N/A

Does the media favor PRTA or KARD?

In the previous week, Kardigan had 1 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Kardigan and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Kardigan's score of 0.14 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kardigan 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRTA or LKFT?

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.71 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lakefront Biotherapeutics American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DMRA or PRTA?

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Prothena (PRTA) Competitors

$9.33 +0.24 (+2.64%)

As of 08/28/2026 04:00 PM Eastern

Compare

PRTA vs. SRPT, ZYME, KARD, LKFT, and DMRA

Should you buy Prothena stock or one of its competitors? Prothena's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Zymeworks (ZYME), Kardigan (KARD), Lakefront Biotherapeutics American Depositary Shares (LKFT), and Damora Therapeutics, Inc. Common Stock (DMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prothena compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Prothena (NASDAQ:PRTA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Sarepta Therapeutics presently has a consensus target price of $25.06, indicating a potential upside of 20.13%. Prothena has a consensus target price of $24.57, indicating a potential upside of 163.36%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Prothena has lower revenue, but higher earnings than Sarepta Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	1.00	-$713.41M	-$2.90	N/A
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A

In the previous week, Sarepta Therapeutics had 9 more articles in the media than Prothena. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Sarepta Therapeutics' score of 1.00 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sarepta Therapeutics has a net margin of -13.48% compared to Prothena's net margin of -80.68%. Sarepta Therapeutics' return on equity of -1.60% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Prothena	-80.68%	-16.45%	-14.51%

Sarepta Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Prothena has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market.

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Prothena beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Prothena compare to Zymeworks?

Prothena (NASDAQ:PRTA) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Zymeworks had 32 more articles in the media than Prothena. MarketBeat recorded 35 mentions for Zymeworks and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Zymeworks' score of 0.91 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zymeworks	12 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena has a net margin of -80.68% compared to Zymeworks' net margin of -405.31%. Prothena's return on equity of -16.45% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Zymeworks	-405.31%	-72.30%	-37.18%

Zymeworks has higher revenue and earnings than Prothena. Zymeworks is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A
Zymeworks	$105.96M	18.93	-$81.13M	-$2.02	N/A

Prothena has a beta of -0.3, meaning that its share price is 130% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Prothena presently has a consensus target price of $24.57, indicating a potential upside of 163.36%. Zymeworks has a consensus target price of $40.00, indicating a potential upside of 41.49%. Given Prothena's stronger consensus rating and higher probable upside, equities analysts clearly believe Prothena is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

97.1% of Prothena shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Prothena beats Zymeworks on 11 of the 17 factors compared between the two stocks.

How does Prothena compare to Kardigan?

Prothena (NASDAQ:PRTA) and Kardigan (NASDAQ:KARD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Kardigan has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Kardigan's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Kardigan	N/A	N/A	N/A

97.1% of Prothena shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kardigan has lower revenue, but higher earnings than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Prothena currently has a consensus target price of $24.57, indicating a potential upside of 163.36%. Kardigan has a consensus target price of $42.25, indicating a potential upside of 111.04%. Given Prothena's higher possible upside, equities analysts clearly believe Prothena is more favorable than Kardigan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Kardigan had 1 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Kardigan and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Kardigan's score of 0.14 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kardigan	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prothena beats Kardigan on 7 of the 12 factors compared between the two stocks.

How does Prothena compare to Lakefront Biotherapeutics American Depositary Shares?

Prothena (NASDAQ:PRTA) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Prothena currently has a consensus target price of $24.57, indicating a potential upside of 163.36%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $30.67, indicating a potential upside of 6.19%. Given Prothena's stronger consensus rating and higher probable upside, research analysts clearly believe Prothena is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Prothena. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.51	$363.05M	-$1.41	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.71 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Prothena has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 10.4% of Prothena shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Prothena beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Prothena compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 3 mentions for Prothena. Prothena's average media sentiment score of 1.80 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $44.00, indicating a potential upside of 51.72%. Prothena has a consensus target price of $24.57, indicating a potential upside of 163.36%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Prothena	-80.68%	-16.45%	-14.51%

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Prothena has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A

Summary

Damora Therapeutics, Inc. Common Stock and Prothena tied by winning 8 of the 16 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$475.89M	$4.02B	$7.24B	$12.93B
Dividend Yield	N/A	3.60%	2.54%	10.96%
P/E Ratio	-11.11	11.56	271.50	25.38
Price / Sales	50.46	1,345.95	623.92	96.47
Price / Cash	N/A	110.59	79.29	54.21
Price / Book	1.70	16.50	12.95	6.14
Net Income	-$244.09M	-$22.76M	$3.46B	$347.93M
7 Day Performance	-1.27%	-0.23%	-0.11%	-0.78%
1 Month Performance	9.00%	11.93%	8.32%	5.60%
1 Year Performance	13.78%	55.61%	24.70%	15.64%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	3.141 of 5 stars	$9.33 +2.6%	$24.57 +163.4%	+13.2%	$475.89M	$9.68M	N/A	130	Positive News
SRPT Sarepta Therapeutics	3.2117 of 5 stars	$18.81 +3.7%	$25.06 +33.3%	+13.7%	$1.99B	$1.97B	N/A	1,372
ZYME Zymeworks	2.8493 of 5 stars	$28.11 -2.3%	$40.75 +45.0%	+90.5%	$1.98B	$105.96M	N/A	460	Trending News Analyst Forecast Analyst Revision
KARD Kardigan	3.6682 of 5 stars	$20.96 +1.6%	$42.25 +101.6%	N/A	$1.96B	N/A	N/A	N/A	News Coverage Analyst Forecast
LKFT Lakefront Biotherapeutics American Depositary Shares	1.3578 of 5 stars	$29.51 +1.6%	$30.67 +3.9%	-10.9%	$1.94B	$1.26B	N/A	1,310	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors

PRTA vs. SRPT, ZYME, KARD, LKFT, and DMRA

How does Prothena compare to Sarepta Therapeutics?

Summary

How does Prothena compare to Zymeworks?

Summary

How does Prothena compare to Kardigan?

Summary

How does Prothena compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Prothena compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Competitors

PRTA vs. SRPT, ZYME, KARD, LKFT, and DMRA

How does Prothena compare to Sarepta Therapeutics?

Do analysts prefer SRPT or PRTA?

Which has stronger valuation and earnings, SRPT or PRTA?

Does the media favor SRPT or PRTA?

Is SRPT or PRTA more profitable?

Which has more risk and volatility, SRPT or PRTA?

Do insiders & institutionals hold more shares of SRPT or PRTA?

Summary

How does Prothena compare to Zymeworks?

Does the media favor PRTA or ZYME?

Is PRTA or ZYME more profitable?

Which has preferable valuation & earnings, PRTA or ZYME?

Which has more volatility & risk, PRTA or ZYME?

Do analysts rate PRTA or ZYME?

Do institutionals & insiders hold more shares of PRTA or ZYME?

Summary

How does Prothena compare to Kardigan?

Is PRTA or KARD more profitable?

Do insiders & institutionals hold more shares of PRTA or KARD?

Which has stronger earnings and valuation, PRTA or KARD?

Do analysts rate PRTA or KARD?

Does the media favor PRTA or KARD?

Summary

How does Prothena compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts recommend PRTA or LKFT?

Which has higher earnings and valuation, PRTA or LKFT?

Does the media refer more to PRTA or LKFT?

Is PRTA or LKFT more profitable?

Which has more volatility & risk, PRTA or LKFT?

Do insiders and institutionals believe in PRTA or LKFT?

Summary

How does Prothena compare to Damora Therapeutics, Inc. Common Stock?

Does the media prefer DMRA or PRTA?

Do analysts prefer DMRA or PRTA?

Is DMRA or PRTA more profitable?

Do institutionals & insiders believe in DMRA or PRTA?

Which has more volatility and risk, DMRA or PRTA?

Which has preferable valuation and earnings, DMRA or PRTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools